Subscribe to email alerts

Embark Health 26/08/2020

MMJ Group Holdings investee Embark Health Inc continues delivering strategic priorities

Embark continues its measured approach to capacity expansion by ensuring initiatives are cost-effective and will be capable of meeting growing consumer demand for 2.0 products.

The manufacturing of solventless 2.0 products forms the basis of Embark’s Health Canada sales licence submission package

MMJ Group Holdings Ltd (ASX:MMJ) investee Embark Health Inc is continuing its focus on delivering strategic priorities for the remainder of 2020 after making significant process in operationalising its Delta Facility.

B2B Solventless 2.0 product sales began in May of 2020 and have continued to scale throughout the North American summer months.

Embark has continued to lift capacity and production capabilities, expanding its customer network, increasing product innovation and submitting its Sales Licence Amendment and Provincial Product Sales Applications.

The company believes that focusing on these priorities will generate long-term shareholder value and accelerate the path to profitability.

Federal sales licence completed

Embark Delta has completed the submission of its federal sales licence amendment to Health Canada as part of the Sales Licence path forward.

The submission of several provincial applications has also been completed for the sale of adult-use 2.0 products; most notably in Alberta and British Columbia.

Embark chief executive officer Dr Luc Duchesne said: “The submission of our sales licence amendment is significant as it represents the successful operationalisation of Embark’s extraction and product manufacturing capabilities.

“Since receiving our processing licence from Health Canada on February 7, 2020, Embark has manufactured Bubble Hash, Traditional Pressed Hash, DrySift and Rosin destined for the adult-use market in Canada.”

“Significant milestones”

The manufacturing of solventless 2.0 products forms the basis of Embark’s Health Canada sales licence submission package, which Embark is committed to continuously improving.

Duchesne continued: “These are significant milestones for Embark as we expand production capacity. 

“Our B2B orders continue to fill our capacity and, upon approval, the sales licence and provincial approvals will allow us to offer a wider range of services and channels to our clients and Embark for the production and distribution of 2.0 products.”

Enhancing production capabilities 

Embark continues its measured and disciplined approach to capacity expansion and production capabilities by ensuring initiatives pursued are cost-effective and will be capable of meeting growing consumer demand for 2.0 products.

Commissioning of the Solventless Extraction equipment for the Delta facility took place in March and April in preparation for May B2B sales. Production lines include Ice Water Extraction, DrySift Extraction in conjunction with Pressing Lines for Rosin and Traditional Pressed Hash.

Innovation-driven organisation

Embark has a strong commitment to innovation throughout its value chain and is continuing to gather internal data as well as leverage market research and insights as a foundation for the development of products with a competitive edge.

The company is continuing to build its portfolio with the Hank and Hazel brands and following the completion of its Axiomm acquisition, Embark will build out the Axiomm brand with its nono-emulsification technology.

Read the full article at

Back to News

Related Articles

Embark Health

Embark Health Investor Update

19/03/2019 Read more
Embark Health

Embark Health Investor Quarterly Update

16/08/2019 Read more
Embark Health

MMJ Group increases investment in Embark Health, valuation nearly triples

17/10/2019 Read more
Embark Health

Embark Health – Corporate Presentation November 2019

07/11/2019 Read more


Subscribe to email alerts